Renal Dysfunction in the Setting of HIV/AIDS
详细信息 查看全文
- 作者：Jose M. Miro (1)
Federico Cofan (2)
Joan C. Trullas (3)
Christian Manzardo (1)
Carlos Cervera (1)
Montserrat Tuset (4)
Federico Oppenheimer (2)
Mercedes Brunet (5)
Asuncion Moreno (1)
Josep M. Campistol (2)
Jose M. Gatell (1) - 关键词：HIV Infection ; AIDS ; Kidney ; Dialysis ; Kidney transplantation ; Antiretroviral therapy ; Immunosuppressive agents ; Proteinuria ; Acute kidney injury ; Chronic kidney failure ; Renal dysfunction
- 刊名：Current HIV/AIDS Reports
- 出版年：2012
- 出版时间：September 2012
- 年：2012
- 卷：9
- 期：3
- 页码：187-199
- 全文大小：264KB
- 参考文献：1. Kalayjian RC. Renal issues in HIV infection. Curr HIV/AIDS Rep. 2011;8:164鈥?1. class="external" href="http://dx.doi.org/10.1007/s11904-011-0080-x">CrossRef
2. Phair J, Palella F. Renal disease in HIV-infected individuals. Curr Opin HIV AIDS. 2011;6:285鈥?. class="external" href="http://dx.doi.org/10.1097/COH.0b013e3283476bc3">CrossRef
3. Bohmart A, Burns G. Renal disease in an urban HIV population in the era prior and following the introduction of highly active antiretroviral therapy. J Natl Med Assoc. 2011;103:513鈥?.
4. Mocroft A, Reiss P, Gasiorowski J, EuroSIDA Study Group, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262鈥?0. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e3181e9be6b">CrossRef
5. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25:1603鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e32834957da">CrossRef
6. Baekken M, Os I, Sandvik L, et al. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant. 2008;23:3130鈥?. class="external" href="http://dx.doi.org/10.1093/ndt/gfn236">CrossRef
7. Szczech L, Menezes P, Byrd Quinlivan E, et al. Microalbuminuria predicts overt proteinuria among patients with HIV infection. HIV Med. 2010;11:419鈥?6.
8. Szczech L, Grunfeld C, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS. 2007;21:1003鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3280d3587f">CrossRef
9. Overton E, Nurutdinova D, Freeman J, et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009;10:343鈥?0. class="external" href="http://dx.doi.org/10.1111/j.1468-1293.2009.00693.x">CrossRef
10. Ando M, Yanagisawa N, Ajisawa A, et al. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923鈥?. class="external" href="http://dx.doi.org/10.1093/ndt/gfr129">CrossRef
11. Choi A, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010; 478鈥?5.
12. Lopes JA, Melo MJ, Viegas A, et al. Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrol Dial Transplant. 2011;26:3888鈥?4. class="external" href="http://dx.doi.org/10.1093/ndt/gfr192">CrossRef
13. Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6:1700鈥?. class="external" href="http://dx.doi.org/10.2215/CJN.09191010">CrossRef
14. Tordato F, Cozzi Lepri A, Cicconi P, ICONA Foundation Study Group, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12:4鈥?3. class="external" href="http://dx.doi.org/10.1111/j.1468-1293.2010.00855.x">CrossRef
15. 鈥?Mocroft A, Kirk O, Reiss P, et al. EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667鈥?8. / A study from the EuroSIDA Study Group that assesses the prevalence of CKD in European HIV-infected patients and the impact of different antiretroviral drug regimens. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e328339fe53">CrossRef
16. D茅ti E, Thi茅baut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11:308鈥?7. class="external" href="http://dx.doi.org/10.1111/j.1468-1293.2009.00780.x">CrossRef
17. Campbell L, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329鈥?6. class="external" href="http://dx.doi.org/10.1111/j.1468-1293.2008.00691.x">CrossRef
18. Di Biagio A, Rosso R, Vitale F, et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: a European case control study. Clin Nephrol. 2011;75:518鈥?3.
19. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120鈥?. class="external" href="http://dx.doi.org/10.1093/cid/cir627">CrossRef
20. Rawlings MK, Klein J, Klingler EP, et al. Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. HIV AIDS (Auckl). 2011;3:1鈥?.
21. Choi A, Li Y, Deeks S, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651鈥?. class="external" href="http://dx.doi.org/10.1161/CIRCULATIONAHA.109.898585">CrossRef
22. George E, Lucas G, Nadkarni G, et al. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24:387鈥?4. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3283359253">CrossRef
23. 鈥?Trullas JC, Mocroft A, Cofan F, et al. EuroSIDA Investigators. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr. 2010;55:582鈥?. / The first study that evaluates the prevalence and characteristics of ESRD patients (including patients on dialysis and renal transplant recipients) from the EuroSIDA Cohort. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e3181efbe59">CrossRef
24. Rodriguez RA, Mendelson M, O鈥橦are AM, et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol. 2003;14:1307鈥?3. class="external" href="http://dx.doi.org/10.1097/01.ASN.0000062963.56513.28">CrossRef
25. Vigneau C, Guiard-Schmid JB, Tourret J, et al. The clinical characteristics of HIVinfected patients receiving dialysis in France between 1997 and 2002. Kidney Int. 2005;67:1509鈥?4. class="external" href="http://dx.doi.org/10.1111/j.1523-1755.2005.00229.x">CrossRef
26. Tourret J, Tostivint I, Tezenas du Montcel S, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol. 2006;1:1241鈥?. class="external" href="http://dx.doi.org/10.2215/CJN.02211205">CrossRef
27. Trull脿s JC, Barril G, Cofan F, The Spanish HIV, Infection in Dialysis Study Group, et al. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses. 2008;24:1229鈥?5. class="external" href="http://dx.doi.org/10.1089/aid.2008.0158">CrossRef
28. Jotwani V, Li Y, Grunfeld C, et al. Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors. Am J Kidney Dis. 2012;59:628鈥?5.
29. George E, Nadkarni GN, Estrella MM, et al. The impact of hepatitis C coinfection on kidney disease related to human immunodeficiency virus (HIV): a biopsy study. Medicine (Baltimore). 2011;90:289鈥?5.
30. Fine DM, Wasser WG, Estrella MM, et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol. 2012;23:343鈥?0. class="external" href="http://dx.doi.org/10.1681/ASN.2011060562">CrossRef
31. Ramsuran D, Bhimma R, Ramdial PK, et al. The spectrum of HIV-related nephropathy in children. Pediatr Nephrol. 2012;27:821鈥?. class="external" href="http://dx.doi.org/10.1007/s00467-011-2074-8">CrossRef
32. Chen P, Chen BK, Mosoian A, et al. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. J Am Soc Nephrol. 2011;22:496鈥?07. class="external" href="http://dx.doi.org/10.1681/ASN.2010040379">CrossRef
33. 鈥?Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22:2129鈥?7. / Excellent study that evaluates APOL1 genotypes in different populations at risk for developing HIVAN. Genetic testing for APOL1 should ideally be included in the clinical practice for care of HIV-infected patients. class="external" href="http://dx.doi.org/10.1681/ASN.2011040388">CrossRef
34. Medapalli RK, He JC, Klotman PE. HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens. 2011;20:306鈥?1. class="external" href="http://dx.doi.org/10.1097/MNH.0b013e328345359a">CrossRef
35. Papeta N, Sterken R, Kiryluk K, et al. The molecular pathogenesis of HIV-1 associated nephropathy: recent advances. J Mol Med (Berl). 2011;89:429鈥?6. class="external" href="http://dx.doi.org/10.1007/s00109-010-0719-x">CrossRef
36. D鈥橝gati VD. Pathophysiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens. 2012;21(3):243鈥?0. class="external" href="http://dx.doi.org/10.1097/MNH.0b013e32835200df">CrossRef
37. Salhan D, Sagar A, Kumar D, et al. HIV-associated nephropathy: role of AT2R. Cell Signal. 2012;24:734鈥?1. class="external" href="http://dx.doi.org/10.1016/j.cellsig.2011.11.007">CrossRef
38. Salhan D, Pathak S, Husain M, et al. HIV gene expression deactivates redox-sensitive stress response program in mouse tubular cells both in vitro and in vivo. Am J Physiol Renal Physiol. 2012;302:F129鈥?0. class="external" href="http://dx.doi.org/10.1152/ajprenal.00024.2011">CrossRef
39. 鈥?Big茅 N, Lanternier F, Viard JP et al. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant. 2012;27:1114鈥?1. / Clinical study that analyzes the outcome of HIV-infected patients with HIVAN. It is important to remark that despite antiretroviral therapy, HIVAN led to ESRD in more than half of the cases. It is crucial to have early recognition of this condition. class="external" href="http://dx.doi.org/10.1093/ndt/gfr376">CrossRef
40. Atta M. Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17:52鈥?. class="external" href="http://dx.doi.org/10.1053/j.ackd.2009.08.005">CrossRef
41. Winston J. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010;17:19鈥?5. class="external" href="http://dx.doi.org/10.1053/j.ackd.2009.08.006">CrossRef
42. Izzedine H, Harris M, Perazella M. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563鈥?3. class="external" href="http://dx.doi.org/10.1038/nrneph.2009.142">CrossRef
43. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.
44. Rockwood N, Mandalia S, Bower M, et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e32834a1cd6">CrossRef
45. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-na茂ve HIV-1-infected patients at 48聽weeks. AIDS. 2008;22:1389鈥?7. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e32830285fb">CrossRef
46. Viglietti D, Verine J, De Castro N, et al. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Antivir Ther. 2011;16:119鈥?1. class="external" href="http://dx.doi.org/10.3851/IMP1700">CrossRef
47. Izzedine H, Valantin M, Daudon, et al. Efavirenz urolithiasis. AIDS. 1992;2007:21.
48. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296鈥?.
49. Bonnet F, Balestre E, Bernardin E, et al. Risk factors for hyperlactataemia in HIV-infected patients. Aquitaine Cohort, 1999鈥?003. Antivir Chem Chemother. 2005;16:63鈥?.
50. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
51. Calza L, Trapani F, Tedeschi S, et al. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-na茂ve patients. Scand J Infect Dis. 2011;43:656鈥?0. class="external" href="http://dx.doi.org/10.3109/00365548.2011.572906">CrossRef
52. Hhall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773鈥?0. class="external" href="http://dx.doi.org/10.1053/j.ajkd.2011.01.022">CrossRef
53. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302鈥?. class="external" href="http://dx.doi.org/10.1038/ki.2011.124">CrossRef
54. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867鈥?5. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e328351f68f">CrossRef
55. Vrouenraets SM, Wit FW, Fernandez Garcia E, et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-na茂ve HIV-1-infected patients. HIV Med. 2011;12:620鈥?1. class="external" href="http://dx.doi.org/10.1111/j.1468-1293.2011.00941.x">CrossRef
56. Haverkort ME, van der Spek BW, Lips P, et al. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis. 2011;43:821鈥?. class="external" href="http://dx.doi.org/10.3109/00365548.2011.577805">CrossRef
57. Kohler JJ, Hosseini SH. Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment. Methods Mol Biol. 2011;755:267鈥?7. class="external" href="http://dx.doi.org/10.1007/978-1-61779-163-5_22">CrossRef
58. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689鈥?6. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3283262a64">CrossRef
59. Post F, Moyle G, Stellbrink H, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-na茂ve, HIV-1-infected adults: 48-week results from the ASSERT Study. J Acquir Immune Defic Syndr. 2010;55:49鈥?7. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e3181dd911e">CrossRef
60. Rodriguez-Novoa S, Labarga P, D鈥橝volio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e32833202e2">CrossRef
61. Kiser J, Carten M, Aquilante C, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265鈥?2. class="external" href="http://dx.doi.org/10.1038/sj.clpt.6100269">CrossRef
62. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108鈥?6. class="external" href="http://dx.doi.org/10.1086/598507">CrossRef
63. Pushpakom SP, Liptrott NJ, Rodr铆guez-N贸voa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204:145鈥?3. class="external" href="http://dx.doi.org/10.1093/infdis/jir215">CrossRef
64. Vescini F, Cozzi-Lepri A, Borderi M, et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011;58:163鈥?2. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e31822e57e9">CrossRef
65. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52:396鈥?05. class="external" href="http://dx.doi.org/10.1093/cid/ciq158">CrossRef
66. Levey A, Stevens L, Schmid C, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604鈥?2.
67. Ibrahim F, Hamzah L, Jones R, et al; on behalf of the UK CHIC/CKD study group. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant. 2012;27:2291鈥?.
68. Dabrowska MM, Mikula T, Stanczak W, et al. Comparative analysis of the new chronic kidney disease epidemiology collaboration and the modification of diet in renal disease equations for estimation of glomerular filtration rate in HIV type 1-infected subjects. AIDS Res Hum Retroviruses. 2011;27:809鈥?3. class="external" href="http://dx.doi.org/10.1089/aid.2010.0233">CrossRef
69. Weinert LS, Camargo EG, Soares AA, et al. Glomerular filtration rate estimation: performance of serum cystatin C-based prediction equations. Clin Chem Lab Med. 2011;49:1761鈥?1. class="external" href="http://dx.doi.org/10.1515/cclm.2011.670">CrossRef
70. Overton ET, Patel P, Mondy K, et al. Cystatin C and baseline renal function among HIV-infected Persons in the SUN study. AIDS Res Hum Retroviruses. 2012;28:148鈥?5. class="external" href="http://dx.doi.org/10.1089/aid.2011.0018">CrossRef
71. Estrella MM, Parekh RS, Astor BC, et al. Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2011;57:380鈥?. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e318222f461">CrossRef
72. Neuhaus J, Jacobs D, Baker J, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788鈥?5. class="external" href="http://dx.doi.org/10.1086/652749">CrossRef
73. 鈥?Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIV-infected patients: promising but not yet ready for prime time. Nephrol Dial Transplant. 2012;27:1305鈥?3. / In the last years, cystatin C is emerging as a promising biomarker for the evaluation of GFR. Data are insufficient to encourage the use of cystatin C or cystatin C鈥揵ased equations to estimate GFR in the HIV-infected population. class="external" href="http://dx.doi.org/10.1093/ndt/gfs001">CrossRef
74. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e32833c3281">CrossRef
75. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 2009;23:1297鈥?10. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e32832ce85a">CrossRef
76. Estrella M, Fine D. Screening for chronic kidney disease in HIV-infected patients. Adv Chronic Kidney Dis. 2010;17:26鈥?5. class="external" href="http://dx.doi.org/10.1053/j.ackd.2009.07.014">CrossRef
77. Wyatt C, Hoover D, Shi Q, et al. Microalbunimuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr. 2010;55:73鈥?. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e3181cc1070">CrossRef
78. Sola-Del Valle DA, Mohan S, Cheng JT, et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant. 2011;26:2387鈥?0. class="external" href="http://dx.doi.org/10.1093/ndt/gfr258">CrossRef
79. Hall A, Edwards S, Lapsley M, et al. Subclinical tubular injury in HIVinfected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54:1034鈥?2. class="external" href="http://dx.doi.org/10.1053/j.ajkd.2009.07.012">CrossRef
80. Maggi P, Montinaro V, Bellacosa C, et al. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2012;26:5鈥?1. class="external" href="http://dx.doi.org/10.1089/apc.2011.0185">CrossRef
81. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889鈥?3. class="external" href="http://dx.doi.org/10.1097/01.ASN.0000019773.43765.BF">CrossRef
82. Trull脿s JC, Cofan F, Barril G, Spanish HIV Infection in Dialysis Study Group, et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276鈥?3. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e318221fbda">CrossRef
83. Sawinski D, Wyatt CM, Casagrande L, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9:1鈥?. class="external" href="http://dx.doi.org/10.1111/j.1600-6143.2009.02637.x">CrossRef
84. 鈥⑩€?Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004鈥?01. / This is the most important experience with renal transplantation in HIV-infected patients. Patient and graft survival rates were high at 1 and 3聽years, with no increases in complications associated with HIV infection. A higher rate of acute rejection was found in comparison with the general transplant population. class="external" href="http://dx.doi.org/10.1056/NEJMoa1001197">CrossRef
85. Martina MN, Cofan F, Suarez A, et al. Kidney transplantation and waiting list for renal transplantation for human immunodeficiency virus patients. Transplant Proc. 2011;43:2179鈥?1. class="external" href="http://dx.doi.org/10.1016/j.transproceed.2011.05.024">CrossRef
86. Yoon SC, Hurst FP, Jindal RM, et al. Trends in renal transplantation in patients with human immunodeficiency virus infection: an analysis of the United States renal data system. Transplantation. 2011;91:864鈥?. class="external" href="http://dx.doi.org/10.1097/TP.0b013e31820f081f">CrossRef
87. 鈥⑩€?Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79:825鈥?2. / Excellent review regarding different issues of renal transplantation in HIV-infected patients. The efficacy of different immunosuppressive regimens, a practical point of view of the antiretroviral management in patients with renal function impairment, and renal transplant recipients and the potential pharmacological interactions between antiretroviral and immunosuppressive drugs are some of the most important topics discussed. class="external" href="http://dx.doi.org/10.1038/ki.2010.545">CrossRef
88. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67:1622鈥?. class="external" href="http://dx.doi.org/10.1111/j.1523-1755.2005.00245.x">CrossRef
89. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355鈥?5. class="external" href="http://dx.doi.org/10.1111/j.1600-6143.2007.02061.x">CrossRef
90. Gruber SA, Doshi MD, Cincotta E, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86:269鈥?4. class="external" href="http://dx.doi.org/10.1097/TP.0b013e318177884e">CrossRef
91. Trullas JC, Cofan F, Cocchi S, et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses. 2007;23:1161鈥?. class="external" href="http://dx.doi.org/10.1089/aid.2007.0015">CrossRef
92. Mazuecos A, Fernandez A, Andres A, et al. HIV infection and renal transplantation. Nephrol Dial Transplant. 2011;26:1401鈥?. class="external" href="http://dx.doi.org/10.1093/ndt/gfq592">CrossRef
93. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant. 2010;10:2263鈥?. class="external" href="http://dx.doi.org/10.1111/j.1600-6143.2010.03258.x">CrossRef
94. Miro JM, Torre-Cisneros J, Moreno A, et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm Infecc Microbiol Clin. 2005;23:353鈥?2. class="external" href="http://dx.doi.org/10.1157/13076175">CrossRef
95. Bhagani S, Sweny P, Brook G. Guidelines for kidney transplantation in patients with HIV disease. HIV Med. 2006;7:133鈥?. class="external" href="http://dx.doi.org/10.1111/j.1468-1293.2006.00367.x">CrossRef
96. Grossi P, Tumietto F, Costigliola P, et al. Liver transplantation in HIV-infected individuals: results of the Italian national program. Transplantation. 2006;82 Suppl 2:446.
97. Gilliam BL, Heredia A, Devico A, et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS. 2007;21:2108鈥?0. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3282f02a4f">CrossRef
98. Bosch RJ, Pollard RB, Landay A, et al. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). AIDS Res Ther. 2010;7:30. class="external" href="http://dx.doi.org/10.1186/1742-6405-7-30">CrossRef
99. Moscoso-Solorzano GT, Baltar JM, Seco M, et al. Single dose of rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report. Transplant Proc. 2007;39:3460鈥?. class="external" href="http://dx.doi.org/10.1016/j.transproceed.2007.09.043">CrossRef
100. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816鈥?0. class="external" href="http://dx.doi.org/10.1111/j.1600-6143.2007.02007.x">CrossRef
101. Carter JT, Melcher ML, Carlson LL, et al. Thymoglobulin-associated CD4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6:753鈥?0. class="external" href="http://dx.doi.org/10.1111/j.1600-6143.2006.01238.x">CrossRef
102. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362:2336鈥?. class="external" href="http://dx.doi.org/10.1056/NEJMc0900837">CrossRef
103. Cofan F, Trullas JC, Cervera C, et al. Are HIV-infected donors suitable for renal transplantation? Transplantation. 2011;91:e22鈥?. class="external" href="http://dx.doi.org/10.1097/TP.0b013e318206fa5d">CrossRef
104. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3282f4706d">CrossRef
105. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21:2809鈥?3. class="external" href="http://dx.doi.org/10.1093/ndt/gfl337">CrossRef
106. Novak JE, Szczech LA. Management of HIV-infected patients with ESRD. Adv Chronic Kidney Dis. 2010;17:102鈥?0. class="external" href="http://dx.doi.org/10.1053/j.ackd.2009.08.014">CrossRef
107. Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother. 2011;12:691鈥?04. class="external" href="http://dx.doi.org/10.1517/14656566.2011.535518">CrossRef
108. Ratnam KK, Feng X, Chuang PY, et al. Role of the retinoic acid receptor-伪 in HIV-associated nephropathy. Kidney Int. 2011;79:624鈥?4. class="external" href="http://dx.doi.org/10.1038/ki.2010.470">CrossRef
109. Zhong Y, Wu Y, Liu R, et al. Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure. Kidney Int. 2012;81:856鈥?4. class="external" href="http://dx.doi.org/10.1038/ki.2011.467">CrossRef
110. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559鈥?5. class="external" href="http://dx.doi.org/10.1086/430257">CrossRef
111. Panel de expertos de Gesida y Plan Nacional sobre el Sida. National consensus document by GESIDA/National AIDS Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Enferm Infecc Microbiol Clin 2011; 29:209.e1鈥?03
112. Antiretroviral agents product information. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Available at: class="a-plus-plus">http://www.emea.europa.eu/htms/human/epar/a.htm. Accessed March 2012.
113. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321鈥?3. class="external" href="http://dx.doi.org/10.1001/jama.2010.1004">CrossRef
114. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr. 2008;47:342鈥?. class="external" href="http://dx.doi.org/10.1097/QAI.0b013e31816237f0">CrossRef
115. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3282f4243b">CrossRef
116. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24:223鈥?0. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3283348944">CrossRef
117. Alstrup K, Kangas I, Laursen AL, et al. Renal transplantation in an HIV-infected patient: pharmacokinetic aspects. Scand J Urol Nephrol. 2011;45:216鈥?. class="external" href="http://dx.doi.org/10.3109/00365599.2010.548081">CrossRef
118. Moreno A, Barcena R, Quereda C, et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS. 2008;22:547鈥?. class="external" href="http://dx.doi.org/10.1097/QAD.0b013e3282f37478">CrossRef
119. Back D, Gibbons S. The University of Liverpool HIV drug interactions website. Available at: ctions.org" class="a-plus-plus">http://www.hiv-druginteractions.org. Accessed March 2012.
120. Tuset M, Miro JM, Codina C, et al. Antiretroviral agents drug-drug interactions website (Spanish). Available at: ccioneshiv.com/" class="a-plus-plus">http://www.interaccioneshiv.com/. Accessed March 2012.
121. Hossain MM, Coull JJ, Drusano GL, et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. 2002;55:41鈥?2. class="external" href="http://dx.doi.org/10.1016/S0166-3542(02)00006-2">CrossRef
122. Sankatsing SU, Hoggard PG, Huitema AD, et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet. 2004;43:823鈥?2. class="external" href="http://dx.doi.org/10.2165/00003088-200443120-00004">CrossRef
123. Lepist EI et al. 51st ICAAC, Sep 17鈥?0, 2011, Chicago, IL. Abstract A1-1724. - 作者单位：Jose M. Miro (1)
Federico Cofan (2)
Joan C. Trullas (3)
Christian Manzardo (1)
Carlos Cervera (1)
Montserrat Tuset (4)
Federico Oppenheimer (2)
Mercedes Brunet (5)
Asuncion Moreno (1)
Josep M. Campistol (2)
Jose M. Gatell (1)
1. Infectious Diseases Service, Hospital Clinic鈥揑DIBAPS, University of Barcelona, Barcelona, Spain
2. Renal Transplant Unit, Hospital Clinic鈥揑DIBAPS, University of Barcelona, Barcelona, Spain
3. Internal Medicine Service, Hospital Sant Jaume de Olot (Girona), University of Girona, Girona, Spain
4. Pharmacy Department, Hospital Clinic鈥揑DIBAPS, University of Barcelona, Barcelona, Spain
5. Toxicology Department, Hospital Clinic鈥揑DIBAPS, University of Barcelona, Barcelona, Spain
文摘
Antiretroviral therapy has been immensely successful in reducing the incidence of opportunistic infections and death after HIV infection. This has resulted in heightened interest in noninfectious comorbidities including kidney disease. Although HIV-associated nephropathy, the most ominous kidney disease related to the direct effects of HIV, may be prevented and treated with antiretrovirals, kidney disease remains an important issue in this population. In addition to the common risk factors for kidney disease of diabetes mellitus and hypertension, HIV-infected individuals have a high prevalence of other risk factors, including hepatitis C and exposure to antiretrovirals and other medications. Therefore, the differential diagnosis is vast. Early identification (through efficient screening) and prompt treatment of kidney disease in HIV-infected individuals are critical to lead to better outcomes. This review focuses on clinical and epidemiological issues, treatment strategies (including dialysis and kidney transplantation), and recent advances among kidney disease in the HIV population.